Olatorepatide (HS-20094)_Dosage, benefits & legal status
Also known as HS-20094, olatorepatidum
A near twin of ribupatide, from a rival company.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Olatorepatide (HS-20094)?
Plain language first. The technical label stays, but it never stands alone.Overview
This is a weekly obesity injection in late-stage testing, and the most useful thing to know about it is how close it is to something already on this site. Ribupatide, from a different Chinese company, has the same chemical backbone except for a single building block in the middle and one extra at the end, and both carry the same fatty chain at a different spot. Two companies arrived at nearly the same molecule and both reported about 19% weight loss in Chinese phase 3 trials. The number everyone quotes for this one, 19.3%, comes from an analysis the sponsor calls the efficacy estimand, and that is not one of the five standard analysis types the international guideline defines. The more conservative figure the same release gives is 18.7%, and the small gap between them is actually the reassuring part.
Olatorepatide is a synthetic 40-residue GLP-1 and GIP dual receptor agonist from Hansoh Pharmaceuticals, carrying a C-terminal amide, an alpha-aminoisobutyric acid at position 2 for protease resistance, and a fatty diacid chain attached through a double ethoxy-ethoxy-acetic acid and gamma-glutamate spacer to the terminal lysine at position 40. There is no polymer, no fusion partner and no disulfide. Its registry sequence differs from ribupatide, already covered here, at exactly one internal position and by one added terminal residue, and both molecules carry the same lipid chain at different attachment points. Regeneron holds rights outside Chinese Mainland, Hong Kong and Macau. A Chinese marketing application was accepted in June 2026 for long-term weight management, and the compound is approved nowhere.
What it's used for
Investigational for long-term weight management, with a Chinese marketing application accepted in June 2026 and a global phase 3 program starting. It is not approved anywhere and is not sold.
How does Olatorepatide (HS-20094) work?
What it does in the body, and where.The receptor targets are the familiar pair. What makes this compound worth a page is how close it is to a molecule already here, and what its headline number actually measures.
- 01One residue from ribupatideThe substance registry gives both sequences. They are identical through the whole backbone except position 14, where this compound has leucine and ribupatide has lysine, and this one adds a lysine at position 40. Both carry the same fatty diacid chain on the same kind of spacer, ribupatide on that position-14 lysine and this one on the added terminal lysine. So two companies independently arrived at near positional isomers, moving the attachment point from the middle of the chain to the end. Tirzepatide, by contrast, diverges from position 13 onward.
- 02The lipid is the half-life strategyThe fatty diacid binds albumin in the bloodstream, so the molecule travels attached to a large carrier protein and escapes both kidney filtration and enzyme attack. The alpha-aminoisobutyric acid at position 2 blocks the enzyme that normally cuts incretin peptides there. Together they buy weekly dosing from a molecule small enough to be made by chemical synthesis, with no polymer and no protein partner.
- 03Two receptors, and a claim that is not testedActivating the GLP-1 receptor slows stomach emptying, suppresses appetite and releases insulin with glucose; adding GIP receptor activity appears to improve weight loss beyond GLP-1 alone, and that is the basis of the whole dual agonist class. The developer describes this molecule as dual-biased, a specific claim about preferring some signaling pathways over others downstream of a receptor. No result in the release tests it, and no readable signaling data supports it.
- 04What the headline number measuresThe international guideline on clinical trial estimands names five strategies: treatment policy, composite, while-on-treatment, hypothetical and principal stratum. Neither label used in this program's release is one of them; both are the sponsor's own terms. In practice the efficacy estimand excludes data after people stop treatment or add another weight-loss drug, making it the flattering analysis by construction, while the treatment-regimen estimand corresponds to treatment policy, counting what the randomized group actually did, and is normally what a regulator treats as primary. The honest reading here is encouraging: the two differ by only 0.6 percentage points at the top dose and 90.1% of participants completed, and a small gap means few people left the protocol. Nobody reports it that way.
A schematic of the compound's mechanism, not a diagnostic image.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
One residue from a molecule already on this site
none- lab-analysisThe registry sequences of this compound and ribupatide are identical except position 14, leucine here against lysine there, plus a lysine added at position 40 here.
- lab-analysisBoth carry the same fatty diacid chain on the same spacer, ribupatide on the position-14 lysine and this one on the terminal lysine. Near positional isomers from two different companies.
- RegulatoryThe code prefixes keep them apart: HS is Hansoh and marks this compound, HRS is Hengrui and marks ribupatide, and KAI is Hengrui's partner outside China.
The week 48 results, and what the labels mean
Investigational- Human trialEfficacy estimand: 12.5%, 17.5% and 19.3% weight loss against 2.7% on placebo. Treatment-regimen estimand: 11.8%, 17.0% and 18.7% against 2.5%.
- No dataNeither label is one of the five estimand strategies the international guideline defines. Both are sponsor terms, and which was the pre-specified primary is not stated anywhere.
- Human trialThe two analyses differ by only 0.6 percentage points at the top dose with 90.1% completion, meaning few people left the protocol. That is the most reassuring thing in the dataset and is never reported as such.
- No dataNo peer-reviewed publication of this trial could be located. Everything is conference and press material.
What the registry shows that coverage does not
none- No dataThe trial name used in every press release appears nowhere in the registry record.
- No dataThe registry lists exactly one institution where releases describe 33 sites, a figure that could not be corroborated.
- RegulatoryThe Chinese registration for the same trial predates the ClinicalTrials.gov posting.
- RegulatoryThe global phase 3 reads its primary endpoint at week 72, not week 48, so its results will not be directly comparable.
Commercial position and what is actually for sale
none- RegulatoryThe partnership is 80 million dollars upfront plus up to 1.93 billion in milestones for rights outside Chinese Mainland, Hong Kong and Macau. The two billion figure in trade press is upfront plus every contingent milestone.
- No dataAn exact search on its registry CAS number returned exactly one commercial result, a laboratory research-reagent catalog entry labeled for research use only, with no consumer-facing retail listing found.
- No dataPack sizes, prices and stock for that listing could not be verified, and the figures on its datasheet are reconstitution examples rather than inventory. By contrast ribupatide is catalogd by at least three laboratory suppliers.
The first error is setting 19.3% against ribupatide's 23.6% as though they were the same measurement. Those come from different trials over different durations, with the 23.6% reflecting only 12 weeks at the top dose, and the two programs' placebo arms differ almost two-fold, and that alone shifts any placebo-adjusted comparison by more than a percentage point. The same program's 48-week figure was 19.2%, essentially identical to this compound's. The second error is quoting 19.3% without saying what produced it: that is the sponsor's efficacy estimand, and it excludes data after people stop treatment or add another weight-loss drug, while its treatment-regimen figure is 18.7%, and neither label is one of the five analysis strategies the international guideline names. The third is reading the Chinese regulatory event as an approval; it is an accepted application. The fourth is the money: 80 million dollars was paid upfront and the two billion in headlines is that plus every milestone that might ever be earned. The fifth is the phrase up to 19.3%, hiding that the lowest dose gave 12.5%. Finally, anyone tempted to compare the coming global trial's results with these should note that it reads its primary endpoint at week 72 rather than week 48.
The published record
Papers about Olatorepatide (HS-20094)
Searched: olatorepatide, olatorepatidum, HS-20094, HS20094.
Left out: ribupatide (THE critical rejection. One internal residue and one terminal addition away from this molecule, from a DIFFERENT company, with its own slug. Both are once-weekly GLP-1/GIP dual agonists carrying the same fatty diacid chain, both out-licensed outside Greater China to a US firm in 2025, both about 19% at 48 weeks in Chinese phase 3, both codes starting with H, both names ending in -patide); HRS9531 (ribupatide's development code. HRS belongs to Hengrui, HS belongs to Hansoh, and the two prefixes differ by one letter); KAI-9531 (the Kailera code for the same Hengrui molecule, a third code for the thing this compound is confused with); tirzepatide (the class benchmark dual agonist, with an enormous literature. It diverges from this molecule from position 13 onward, so it is a genuinely different peptide and not a near twin); GLP-1 (the receptor class term, tens of thousands of records); Hansoh (the developer's name, spanning a portfolio including pegloxenatide, added in this same batch); Regeneron (the ex-China licensee, whose other programs are unrelated).
12 papers tagged human · 0 not reviews or lab · 0 clinical trial publications
12 registered trials · none with posted results
Furthest stage reached: Phase 3, completed, no results posted
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.
At a glance
Four things to know about Olatorepatide (HS-20094)
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
Long enough for weekly dosing; no published human figure located
How much, and do you cycle it?
The range, and whether you take breaks.5, 10 or 15 mg once weekly in the phase 3, once weekly. Continuous weekly dosing Trial dose
Trialed as a chronic weekly treatment for weight management, titrated upward rather than cycled.
How long does it stay in the body?
The half-life, and where the figure comes from.Long enough for weekly dosing; no published human figure locatedNo figure
Dosed once weekly throughout the program, so the half-life is of the order of days, but no measured human value appears in any source we could reach, and no pharmacokinetic publication for this compound could be located. The mechanism is albumin binding through the fatty diacid chain, combined with the protease-resistant residue at position 2.
You can compare this against the whole library to see where it sits.
How is it given?
Dosing context and source notes.Investigational and not sold, so no vial draw can be shown and the calculator does not apply. The phase 3 tested 5, 10 and 15 mg once weekly against placebo over 48 weeks. Dose levels for the coming global trial are not stated in its registry record.
How do you store it?
Before mixing, and after.Nothing to store: it is not sold anywhere.
Olatorepatide (HS-20094) has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.
What are the side effects and cautions?
Known cautions and warnings for this compound.Solubility, computed: 20% charged residues, 45% hydrophobic. Base may help.
A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.
Who should avoid it
- Comparing its 19.3% with ribupatide's 23.6% as though the two were measured the same way, since those come from different trials over different durations with placebo arms that differ almost two-fold
- Treating the Chinese regulatory acceptance as an approval, since it is an accepted application and the compound is approved nowhere
- Expecting the coming global trial to be comparable, because its primary endpoint reads at week 72 rather than week 48
Stop and get help
- Severe or persistent abdominal pain, a possible sign of pancreatitis in this drug class
- Persistent vomiting or diarrhea with an inability to keep fluids down
- Signs of an allergic reaction, including rash, swelling or difficulty breathing
Common effects
- Diarrhea was the most common, at 16.9% against 7.8% on placebo in the phase 3.
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Olatorepatide (HS-20094) approved?
And where the numbers on this page come from.No. Olatorepatide (HS-20094) is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous injection, once weekly)
- Checked5 November 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
What has happened recently
Nothing is approved. China's NMPA accepted a marketing application on June 3, 2026 for long-term weight management, and acceptance is not approval. The Regeneron agreement of June 2, 2025 covers rights outside Chinese Mainland, Hong Kong and Macau for 80 million dollars upfront plus up to 1.93 billion dollars in milestones and low-double-digit royalties, so the two billion dollar figure in trade press is the upfront payment plus every contingent milestone rather than money received. US status: an openFDA query returned nothing against five records for semaglutide as a control, and a DailyMed search returned nothing against nine for the same control. On naming, the compound does hold an international nonproprietary name, code 12987, with the Latin form olatorepatidum, but whether that name is proposed or recommended, and which list carried it, could not be established: one proposed list definitively does not contain it and another could not be read to the end. The code prefixes are the reliable way to keep the Chinese dual agonists apart: HS belongs to Hansoh and marks this compound, HRS belongs to Hengrui and marks ribupatide, and KAI belongs to Kailera, Hengrui's partner outside China.
You can compare this against the whole library, or read how to check a seller.
What else is like Olatorepatide (HS-20094)?
Others in GLP-1 agonists, side by side.If you're weighing Olatorepatide (HS-20094), it's worth reading Oxyntomodulin (OXM), Pegloxenatide (Fulaimei), and Pemvidutide in the same class.
A near twin of ribupatide, from a rival company.
- Dose
- 5, 10 or 15 mg once weekly in the phase 3
- How often
- Once weekly
A natural gut hormone that switches on both GLP-1 and glucagon receptors, the blueprint for mazdutide and survodutide. Never developed as a medicine; the human data are a few small studies of 4 weeks or less.
- Dose
- 400 nmol (about 1.8 mg) under the skin before meals, three times daily (research studies)
- How often
- Three times daily, before meals (research)
A weekly GLP-1 whose label says it does not cause weight loss.
- Dose
- 0.1 or 0.2 mg once weekly, the two approved strengths
- How often
- Once weekly
An experimental weekly shot for weight loss and fatty liver.
- Dose
- 1.2 up to 2.4 mg per week (trial doses)
- How often
- Weekly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- ClinicalTrials.gov record NCT06839664, the phase 3 weight-management trial(2026)Organization study ID HS-20094-301, 604 participants actual, completed, 5, 10 and 15 mg weekly against placebo over 48 weeks, with co-primary endpoints of percent weight change and the proportion losing at least 5% at week 48. Two things the registry shows that coverage does not: the trial name used in every press release appears nowhere in the registry record, and the record lists exactly one institution where releases describe 33 sites. A Chinese registration for the same trial was first public on October 31, 2024, earlier than the ClinicalTrials.gov posting.
- ClinicalTrials.gov record NCT07896265, the global phase 3(2026)Sponsored by Regeneron, phase 3, 3,000 participants estimated, not yet recruiting, first posted October 26, 2026 with an estimated start of November 18, 2026, three dose arms plus two placebo arms with the milligram levels not stated. The detail that matters for anyone planning to compare results: its primary endpoint is percent weight change to week 72, not week 48, so its future numbers will not be directly comparable with the Chinese phase 3.
- FDA substance registration record for olatorepatide(2026)UNII AB29LD7VUQ, CAS 2675496-01-0, international nonproprietary name code 12987. A 40-residue synthetic peptide with a C-terminal amide, alpha-aminoisobutyric acid at position 2, and acylation on the terminal lysine. This record is also the source for the comparison with ribupatide, whose sequence in the same registry differs only at position 14 and by the absence of the terminal lysine. Molecular weight is recorded only as greater than 1000, so the precise figure in circulation comes from a supplier datasheet rather than the registry and is not asserted here.
- Developer release reporting the week 48 phase 3 results, presented at a European diabetes meeting(2026)Dated October 2, 2026, and the only source giving per-dose values and naming both analyses. Efficacy estimand at week 48: 12.5%, 17.5% and 19.3% weight loss against 2.7% on placebo. Treatment-regimen estimand: 11.8%, 17.0% and 18.7% against 2.5%. 604 randomized one to one to one to one, 90.1% completed, waist circumference down 10.5, 14.4 and 16.0 cm against 3.6 cm. Pooled adverse events against placebo: diarrhea 16.9% against 7.8%, nausea 7.8% against 2.6%, vomiting 4.9% against 2.0%, constipation 5.1% against 1.3%, with no discontinuations for treatment-related events. These are conference and press figures, not a peer-reviewed publication, and no publication for this trial could be located.
Beyond these, 12 records are indexed. Browse the records